A Phase 4 interventional study of Standard-Dose Influenza Vaccine and MF59-Adjuvanted Influenza Vaccine in Influenza, Influenza Vaccines and Microbiome, sponsored by Korea University Guro Hospital. Completed at 1 site in South Korea. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Korea University Guro Hospital · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing MF59 in Influenza, Human — 3 open to participants now, 3 under way, 1 of them phase 3. MF59 · Influenza, Human.
Among the 22 studies testing MF59 in Influenza, Human, this one is the 20th largest by enrollment, is one of 3 that started in 2025, is one of 3 in phase 4, and was the 21st registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →3 of the 22 studies testing MF59 in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
National Taiwan University Hospital
Ages 50+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 10 · Phase 4 3
First in 2006; this study’s year is marked. 3 started in 2025.
This study's enrollment of 121 is below the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 549 across the 22 interventional studies. Of the 19 that completed or were terminated, 10 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
Korea University Guro Hospital is the lead sponsor of 90 studies on the registry; 17 are open to participants now.
Korea University Guro Hospital has 7 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
2 of the studies testing MF59 in Influenza, Human that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07485855Phase 3Asan Medical CenterInfluenza Vaccination Strategy for Patients With Hematologic Malignancy | 2027-04-30 |
| NCT07126652National Taiwan University HospitalSerological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing MF59 in Influenza, Human, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This prospective, randomized, open-label clinical study aims to evaluate the immunogenicity and underlying immune mechanisms of different influenza vaccine formulations in adults aged ≥65 years. Additionally, the study investigates the role of the gut microbiome in modulating vaccine-induced immune responses and durability.
Despite high influenza vaccination coverage among older adults in Korea, vaccine effectiveness remains suboptimal, even during well-matched seasons. Immunosenescence and microbiome dysbiosis are believed to contribute to reduced vaccine responsiveness.
This study will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: Standard-dose quadrivalent influenza vaccine (Vaxigrip®) Dose: 0.5 mL intramuscular injection, single dose
Biological: Standard-Dose Influenza Vaccine
Intervention: MF59-adjuvanted vaccine (FLUAD®) Dose: 0.5 mL intramuscular injection, single dose
Biological: MF59-Adjuvanted Influenza Vaccine
Intervention: High-dose influenza vaccine (Efluelda®) Dose: 0.7 mL intramuscular injection, single dose
Biological: High-Dose Influenza Vaccine
0.5 mL intramuscular injection, single dose
0.5 mL intramuscular injection, single dose
0.7 mL intramuscular injection, single dose
Seroconversion Rate
≥4-fold increase in hemagglutination inhibition (HI) antibody titers
Time frame: 4 weeks post-vaccination
Geometric Mean Titers
Geometric Mean Titers (GMTs) of HI antibodies
Time frame: Baseline, Day 7, Week 4, Month 6
Cellular Immune Responses
ELISpot (IFN-γ), activated T-cell frequency (CD38, HLA-DR)
Time frame: Baseline, Day 7, Week 4
B Cell Responses
HA-specific B cell frequencies (A/H1N1, A/H3N2, B strains)
Time frame: Baseline, Day 7, Week 4
Microbiome Diversity and Composition
Alpha diversity (Shannon index) Beta diversity (PERMANOVA)
Time frame: Baseline and Week 4
Microbiome Biomarker Identification
Taxonomic and functional markers using LEfSe analysis
Time frame: Baseline, Week 4
Durability of Immune Response
Antibody decay rate (half-life analysis)
Time frame: Baseline, Week 4, Month 6
Safety Outcomes
Solicited adverse events (within 7 days) Unsolicited adverse events (within 30 days)
Time frame: Day 7, Day 30
Plan to share: Yes — Individual participant data (IPD) that underlie the results reported in this study, after de-identification, will be made available to researchers upon reasonable request. Access will be granted following review and approval by the study investigators and institutional review board, in accordance with applicable regulations and data sharing policies.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Data will be available beginning 6 months following publication of the primary results and will remain available for 5 years.
Access criteria: Access to de-identified individual participant data and supporting documents will be provided to qualified researchers with a scientifically sound proposal. Requests will be reviewed and approved by the study investigators and the institutional review board. Data will be shared under a data use agreement to ensure participant confidentiality and compliance with applicable regulations.
Data sharing details ↗ · irb.kumc.or.kr
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Jan 2026, 3 months.
Of 101 non-industry phase 4 interventional studies under Influenza, Human, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 52. This study's 3 months is below that.
Counting every sponsor, half of 138 studies reached it within 14 months; a quarter within 3 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MF59
Korea University Guro Hospital